Previous reviews have shown that changes in prescription drug insurance benefits can affect medication use and adherence. We conducted a systematic review of the literature to identify studies addressing the association between prescription drug coverage and health outcomes. Studies were included if they collected empirical data on expansions or restrictions of prescription drug coverage and if they reported clinical outcomes.
We found 23 studies demonstrating that broader prescription drug insurance reduces use of other health care services and has a positive impact on patient outcomes. Coverage gaps or caps on drug insurance generally led to worse outcomes. States should consider implementing the Affordable Care Act expansions in drug coverage to improve the health of low-income patients receiving state-based health insurance. HEALTH CARE COSTS ARE one of the most important modern-day health policy issues. The United States spends more per capita on health care than any other country, with the percentage of gross domestic product dedicated to health care doubling from 9% in 1980 to 18% in 2011. 1 Costs related to implementation of the federal Medicare health insurance program are considered one of the key contributors to slowed US economic expansion. 2 Prescription drugs have been substantial contributors to health care inflation. Pharmaceuticals account for about 10% of total health care costs, and although spending on pharmaceuticals has recently slowed, it is poised to swell in upcoming years as a result of the increasing prices of complex specialty medicines. 3 One response to this trend from public and private insurers has been to place firm restrictions on the availability of prescription drugs or to exclude certain drugs from coverage altogether. In 2009, Medicaid, the federal-and statefunded health care insurance program for the poor, spent about $25 billion on pharmaceuticals, making it one of the largest single purchasers of prescription drugs in the United States. 4 Collateral effects will emerge from insurance changes that restrict the availability of prescription drugs or exclude patients from accessing them. One predictable effect will be on spending. Numerous previous studies have shown that expenses related to broader insurance coverage of essential prescription drugs result in lower or the same level of overall health care spending. 6---11 For example, in their randomized study of prescription drug coverage expansion, Choudhry et al. found that increased spending by one large insurer on prescription drugs in the form of reduced enrollee copays on certain categories of drugs did not lead to overall increases in health costs. 12 Another expected collateral effect will be on medication adherence. A recent systematic review of value-based insurance design programs, in which patient copayments were reduced for medications used to treat chronic diseases, showed that reduced outof-pocket patient spending was consistently associated with improved medication adherence. 13 Although the effects of drug insurance design changes on health care spending and medication adherence have been demonstrated, the effects on patient morbidity and mortality are less well understood. With the recent limits in drug coverage enacted by certain state Medicaid programs and the possibility of substantial expansion of drug insurance benefits offered by the implementation of the Affordable Care Act (Pub L No. 111-148), we conducted a systematic review to determine how expansions or restrictions in prescription drug insurance have affected patients' health outcomes or their use of health care services.
METHODS
We first searched the MEDLINE database via the OvidSP gateway in May 2014. Literature reviews in related subject areas and the abstracts of known studies helped us formulate the search strategy and identify a comprehensive list of search terms. We settled on 3 main subject heading domains: terms focusing on prescription drug insurance (for example, "insurance" or "coverage"), terms relating to pharmaceuticals or prescription drugs (for example, "drug" or "pharmaceutical"), and terms indicating our outcomes of interest (for example, "outcome assessment" or "health status"). Articles containing at least one search term in each of the 3 main categories met the criteria for our title and abstract review. Searches were limited to human studies and English-language studies; we did not include any date restrictions.
The following Boolean search terms were used: ("prescription drugs" or "prescription" or "drugs" or "drug utilization/economics" or "drug utilization/statistics & numerical data" or "pharmaceutical services" or "pharmacy services" or "drug utilization") and ("reimbursement mechanisms" or
Study Selection
Our review focused on populations of patients who had prescription drug insurance coverage. We excluded studies of patients with health insurance in which the prescription drug insurance component was not separately analyzed. The intervention or exposure of interest was expansion or restriction of prescription drug coverage. Studies were included if they collected empirical data comparing outcomes of patients before and after the expansion or restriction or if they compared patients with prescription drug insurance with a comparator population of patients without such insurance. We included only studies reporting clinical outcomes, which included use of health care services but not simply measurements of costs or health care spending related to service use. We excluded studies of prescription drug insurance benefit design changes that evaluated only effects on drug prescribing, 14, 15 expenditure patterns, 16 or medication adherence alone. 17 Although these measures are of key public health importance, we chose to focus on studies that directly evaluated patient health outcomes. These inclusion criteria did not allow for condition-specific formulary alterations such as those characteristic of value-based insurance designs, 13 nor did they allow for alterations in drug insurance benefit features such as changes in copayments or institution of prior authorization requirements. 18 Even though such programs may affect patient outcomes, we chose to focus on broader drug coverage expansions or restrictions. Studies available for inclusion could have randomized, nonrandomized, controlled, prospective, retrospective, or natural experiment designs. Policy reviews that were not data driven and economic simulations were excluded. Two of the authors (Aaron S. Kesselheim and Lisa A. Fulchino) reviewed all of the abstracts in the search results independently and compared their results; disagreements were resolved by consensus (j = 0.52). Manual reference mining of studies and other reviews supplemented our search results.
Data Extraction, Risk of Bias Determination, and Analysis
Data were extracted and checked by 2 abstractors (Krista F. Huybrechts and Lisa A. Fulchino), with disagreements resolved by consensus. Variables included study design, the nature of the intervention related to prescription drug insurance, study population and size, outcomes, and the funding source or sources for the trial.
We used the guidelines outlined in the Cochrane Handbook for Systematic Reviews of Interventions to evaluate all studies according to their methodological qualities and to assess the studies with respect to bias. These guidelines incorporate 6 parameters: generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias. 19 The handbook outlines suggestions for determining low and high risk in each category. 19 After extraction of data, 2 of the authors (Lisa A. Fulchino and Danielle L. Isaman) independently assessed the studies for possible bias. The reviewers' results were compared, and discrepancies were resolved via consensus among all of the authors. We defined low risk as "plausible bias unlikely to seriously alter the results," unclear risk status as "plausible bias that raises some doubt about the results," and high risk as "plausible bias that seriously weakens confidence in the results." We also included a domain that would capture any additional sources of bias other than those already specified. We then determined overall bias on the basis of assessments of aggregate bias and the potential of sources of bias to affect the magnitude or direction of the results (in accordance with the Cochrane Handbook). Next, we separated the studies into 3 relevant categories to facilitate our evaluation: studies comparing outcomes between patients with and without drug insurance coverage, studies evaluating expansions of drug insurance, and studies evaluating restrictions on drug insurance. Because of the heterogeneity among studies (e.g., in populations, interventions, and outcomes evaluated), a metaanalysis was not possible.
RESULTS
Our search identified 1918 unique publications, of which 40 appeared to meet our inclusion criteria. Nineteen of these articles were excluded after a full-text review, and 2 were added after mining of references in reviewed articles (Figure 1 ). The 23 articles forming our review sample were published between 1990 and 2013, and nearly all (22) investigated insurance changes in the United States. Patients receiving government-sponsored drug insurance were the primary population studied.
We found no randomized controlled trials among these studies. Rather, most were designed as pre-observational/post-observational studies. Study sample sizes ranged from as low as 36 to as high as 157 275 (the median sample size was 2369), with larger study populations associated with analyses of large insurer claims databases. Most populations were health insurance enrollees for whom the presence or absence of prescription drug insurance coverage could be used as a distinguishing variable.
Outcomes Among Patients With and Without Drug Insurance
We found 7 studies that evaluated the impact of drug insurance on patients' health by comparing cohorts of patients with and without coverage ( In the only non-US-focused study in our review, Bleich et al. 24 surveyed patients in different areas of Mexico. They found that patients with drug insurance and hypertension had higher odds of receiving a prescription for an antihypertensive drug and receiving antihypertensive treatment than a propensity-score-matched sample of hypertensive patients without drug insurance. A fourth study that examined the association between health insurance and smoking cessation outcomes (quitting attempts and rates) showed no significant difference in quitting attempts or rates; however, this study involved a high risk of bias. 25 
Drug Insurance Expansions and Patient Health Outcomes
Eight studies reviewed the effects of extending drug coverage to patients on their health outcomes (Table 2 ). In 3 of these studies, initiation of Medicare Part D drug insurance in 2006 was the key policy intervention. Afendulis et al., 26 studying adults across 23 states with at least one "medication-sensitive condition" (a condition that can be improved by drug adherence, such as congestive heart failure or stroke), found that initiation of Part D coverage was associated with a significant reduction from baseline in hospitalizations for such conditions. They estimated that the introduction of Part D was responsible for half of the reduction in admissions occurring in those states during the 2005---2007 time period. Donohue et al. found enrollment in Medicare Part D to be associated with a reduction (from approximately 3% to 2%; P = .03) in the percentage of prescriptions for a set of high-risk drugs previously defined by the National Committee for Quality Assurance as drugs that should be avoided in elderly patients. 27 By contrast, Liu et al. 28 studied communitydwelling patients in the year before and year after Part D coverage was initiated. Part D coverage was associated with an overall decrease in out-of-pocket drug costs (from $854 to $599; P < .001) but was not associated with changes in use of health services, including emergency department visits and hospitalizations. This study was limited by its small sample size and the use of a nearelderly (rather than an agematched) comparison group. Another 2 studies evaluated loosening of previously strict drug insurance caps. Kozma et al.
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Note. CI = confidence interval; COPD = chronic obstructive pulmonary disease; OR = odds ratio; VA = Veterans Affairs. found no statistically significant difference in either physical or mental quality of life among patients who received a subsidy for prescription drugs. In their study of renal transplant recipients, Chisholm et al. 33 concluded through preenrollment/postenrollment comparisons that a medical assistance program was associated with improvements in key clinical outcomes, including blood sugar control, target blood levels of cyclosporine antirejection therapy (although tacrolimus levels were unchanged), and a reduction in the number of graft rejections (P = .008).
Drug Insurance Restrictions and Patient Health Outcomes
Eight studies evaluated the effects of drug insurance restrictions on health outcomes (Table 3) . Only one study (Fuller et al. 34 )
examined complete withdrawal of drug insurance. That study assessed the impact of the Oregon Medicaid program's elimination of its methadone benefit program, which had previously been available to patients with opioid addiction. The authors found that enrollees who left the program after the elimination of coverage had a 75% rate of self-reported heroin use over the next year, as compared with a rate of approximately 33% among patients who paid for the methadone themselves or did not lose their coverage benefits. However, this study was uncontrolled and was methodologically the weakest in our review.
Five of the studies in this category examined the effects of firm caps on drug benefits that arose after patients expended a certain baseline amount of resources on prescription drugs. Four assessed the impact of reaching the coverage limitation built into the Part D benefit. Raebel et al. 35 found that, among patients who had recently obtained insurance through Medicare Part D, reaching the coverage limitation was associated with increases in emergency Significant increase in use of antihypertensives (P < .001), antidiabetics (P = .004), and antilipemics (P = .001); significant decrease in fasting blood glucose, glycosylated hemoglobin, LDL cholesterol, total cholesterol, triglycerides, blood pressure, and graft rejections (P < .01); significant increase in number of patients reaching target serum cyclosporine levels (P = .007)
but not serum tacrolimus levels (P = .343); significant increase in health-related quality of life (P < .01)
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Note. CI = confidence interval DAE = drugs to avoid in the elderly; ROR = relative odds ratio. Two studies conducted by Polinski et al. also evaluated the effects of reaching the Part D beneficiary limit. One showed that beneficiaries reaching the coverage limitation were more likely to discontinue prescribed medications 37 ; however, after control for numerous demographic factors and comorbidities, there were no significant differences in rates of death, hospitalizations related to acute coronary syndrome, or other clinical outcomes. 38 The other Polinski et al. study, the only investigation not relating to the Part D coverage gap, assessed the impact of a $1000 annual drug benefit cap imposed by Medicare + Choice prescription drug coverage plans. 39 Patients with the capped insurance plan, as compared with another cohort of enrollees in the same health plan with unlimited supplemental drug coverage, were more likely to have worse control of their blood pressure, cholesterol, and diabetes. Finally, 2 studies conducted by Soumerai et al. examined how a strict 3-drug coverage benefit cap imposed by the state of New Hampshire in 1981 affected health outcomes. The study patients were compared with a matched cohort in New Jersey, where a cap was not imposed. In the first study, the authors found that the 3-drug cap in the context of elderly patients led to a more than doubling of the relative risk of nursing home admissions (RR = 2.2; 95% CI = 1.2, 4.1). 40 In the second study, they found that the cap led to a 43% to 57% increase in outpatient mental health visits among patients with psychiatric conditions (P < .001) as well as an increase in use of emergency mental health services.
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Risk of Bias Assessment
Our risk of bias assessment (Table 4) showed that most studies were of high quality, and overall the risk of bias was low. Because many of the studies were not randomized prospective trials, some of the quality assessment tools did not apply, and it was particularly difficult to determine the presence or absence of selective reporting. All of the studies consistently ranked highly with respect to reports of full outcome data.
DISCUSSION
Our systematic review of studies evaluating patient health status and health care service use related to possession of prescription drug insurance shows that such programs can have significant effects on both outcomes. Benefits were demonstrated in a variety of clinical circumstances, geographic regions, and temporal settings.
The link between drug insurance expansion and patient health outcomes might be mediated by a number of different mechanisms. One contributor is the improved access to prescription drug therapies offered by enhanced insurance coverage. Patients without insurance may obtain episodic care in an emergency department, but the health effects derived from most prescription therapeutics accrue after ongoing treatment. Consistent access is a key feature of stable insurance coverage. For example, in the Bhattacharya et al. study of outcomes among patients with HIV, the observed improvements in health were a direct result of the life-saving antiretroviral therapy made available to patients through their prescription drug insurance. Clearly, by reducing financial strain on patients, prescription drug insurance helps insulate them from cost-related medication nonadherence and helps advance their health outcomes.
Whether insurance coverage has a positive or negative effect on health care outcomes has become particularly controversial 42 because the Affordable Care Act now authorizes the federal government to offer substantial resources to states for the purposes of expanding Medicaid. Although the federal government plans to cover the full cost of the expansion 45, 46 A prospective randomized study conducted in Oregon, where a Medicaid expansion was implemented through a lottery process in 2008, also demonstrated better self-reported physical and mental health among those who received health insurance. 47 After 2 years of observation, the experience in Oregon has shown inconsistent effects on health promotion, with significant improvements in access to care and reductions in financial strain from medical costs but insignificant changes in clinical markers of hypertension and diabetes control (however, the study was underpowered for these clinical outcomes). 48 Notably, effects on health care outcomes or health service use were not observed in all of the studies we identified. In some cases, the effects seen might be explained by the short-term time windows assessed. For example, studying a population sample after only 1 year of coverage, Liu et al. found reductions in out-of-pocket medication costs and increases in prescription drug use but no impact on outcomes. In other cases, negative outcomes may have been consequences of the study designs. For example, Khan and Kaestner found no statistically significant evidence of health benefits in a survey of elderly patients who self-reported changes in health and disability status, in part because their sample also reported limited changes in their use of prescription drugs after obtaining insurance. 49 Their study showed a nonsignificant trend toward beneficial outcomes among a chronically ill subgroup of the population.
Limitations
Our results should be interpreted with caution given that many of the studies reviewed were conducted during years when costly brand-name drugs were more likely to be prescribed than is the case today, allowing for a greater impact of drug insurance programs. Recently the percentage of prescriptions filled with generic drugs has reached nearly 80% owing to patent expirations of top-selling drugs for a range of different medical conditions. As a result, patients now can be prescribed a wide variety of generic alternatives for many common medication-responsive diseases, such as hypertension and diabetes, offered at prices as low as $4 per month. Use of generic drugs helps address many issues that account for the health benefits of drug insurance, such as cost-related medication nonadherence. Thus, the effect of insurance may be less pronounced in the presentday market, in which generic products are more widely available. Moreover, insurance for generic medications should be rather inexpensive and should promote adherence, which in turn reduces morbidity and its associated costs.
Our conclusions are also limited by the heterogeneity of the studies we identified, many of them examining different aspects of health care delivery and incorporating a variety of methodological approaches and outcome definitions. This heterogeneity prevented us from conducting a quantitative meta-analysis of the results, which would have given greater weight to the findings of the larger studies. To account for heterogeneity, we focused our interpretation on the studies with the largest sample sizes. Another major limitation of our study is the possibility of publication bias. Most of the studies in our sample were retrospective observational investigations, which are not required to be prospectively registered with a trial disclosure database such as ClinicalTrials.gov. Thus, we cannot exclude the possibility that studies were conducted but not completed or published.
Conclusions
Despite the limitations just described, we believe our systematic review shows that substantial evidence supports the central role effective prescription drug insurance can play as policymakers seek mechanisms to reduce the rising health care costs in the United States. Expanding insurance benefits may lead to initial costs in administration, but these costs should be offset by reductions in spending associated with preventable patient morbidity and mortality. Other strategies aimed at increasing the accessibility of essential prescription drugs, such as timely availability of generic alternatives and policies designed to improve medication adherence, will help augment the salutary effects of prescription drug insurance on patient health outcomes. j
